Common variant of farnesoid-x-receptor gene enhances the response to lipid-lowering therapy

被引：0
|
作者：
Nohara, A.
Tada, H.
Katsuda, S.
Kawashiri, M.
Inazu, A.
Kobayashi, J.
Yamagishi, M.
Mabuchi, M.
机构：
[1] Kanazawa Univ, Grad Sch Med Sci, Dept Lipidol, Kanazawa, Ishikawa 920, Japan
[2] Kanazawa Univ, Grad Sch Med Sci, Div Cardiovasc Med, Kanazawa, Ishikawa 920, Japan
[3] Kanazawa Univ, Sch Hlth Sci, Kanazawa, Ishikawa 920, Japan
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2007年 / 8卷 / 01期
关键词：
D O I：
10.1016/S1567-5688(07)70966-2
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [21] Lipid-lowering therapy in patients with a 'normal' LDL-C Authors' response
    Nelson, Adam
    Nicholls, Stephen
    AUSTRALIAN PRESCRIBER, 2024, 47 (03) : 94 - 94
  • [22] Response to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection
    Silverberg, Michael J.
    Leyden, Wendy
    Hurley, Leo
    Go, Alan S.
    Quesenberry, Charles P., Jr.
    Klein, Daniel
    Horberg, Michael A.
    ANNALS OF INTERNAL MEDICINE, 2009, 150 (05) : 301 - +
  • [23] A paucimorphic variant in the HMO-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study
    Donnelly, Louise A.
    Doney, Alex S. F.
    Dannfald, Jennifer
    Whitley, Adrian L.
    Lang, Chim C.
    Morris, Andrew D.
    Donnan, Peter T.
    Palmer, Colin N. A.
    PHARMACOGENETICS AND GENOMICS, 2008, 18 (12): : 1021 - 1026
  • [24] Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia
    Sun, XM
    Patel, DD
    Knight, BL
    Soutar, AK
    ATHEROSCLEROSIS, 1998, 136 (01) : 175 - 185
  • [25] Frequency of Common Variants in Genes Involved in Lipid-Lowering Response to Statins in Chilean Subjects with Hypercholesterolemia
    Rosales, Alexy
    Pacheco, Alejandro
    Cuevas, Alejandro
    Saavedra, Nicolas
    Zambrano, Tomas
    Lanas, Fernando
    Salazar, Luis A.
    INTERNATIONAL JOURNAL OF MORPHOLOGY, 2011, 29 (04): : 1296 - 1302
  • [26] Pharmacogenetics of apolipoprtein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease
    Nieminen, Tuomo
    Kahonen, Mika
    Viiri, Leena E.
    Gronroos, Paula
    Lehtimaki, Terho
    PHARMACOGENOMICS, 2008, 9 (10) : 1475 - 1486
  • [27] Dose escalation pharmacokinetics and lipid lowering activity of a novel farnesoid X receptor modulator: 16-Dehydropregnenolone
    Kumar, Devendra
    Khanna, Ashok K.
    Pratap, Ram
    Sexana, Jitendra K.
    Bhatta, Rabi S.
    INDIAN JOURNAL OF PHARMACOLOGY, 2012, 44 (01): : 57 - 62
  • [28] Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: Mechanistic and clinical studies
    Dergunov, A. D.
    BIOMEDICINE & PHARMACOTHERAPY, 2011, 65 (08) : 597 - 603
  • [29] The role of the CYP3A4 gene variants in lipid-lowering efficacy of simvastatin therapy
    Alzahrani, Sarah A.
    Dzimiri, Nduna
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (06) : E57 - E57
  • [30] Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome
    Rafeeq, Misbahuddin M.
    Ahmad, Farida
    Rahman, Syed Z.
    Siddiqi, Sheelu S.
    Shakil, Shazi
    PHARMACOGENOMICS, 2016, 17 (18) : 2015 - 2024
12345